Based on the MEDEXUS PHARMACEUTIC. stock forecast from 0 analysts, the average analyst target price for MEDEXUS PHARMACEUTIC. is not available over the next 12 months. MEDEXUS PHARMACEUTIC.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MEDEXUS PHARMACEUTIC. is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, MEDEXUS PHARMACEUTIC.’s stock price was EUR 1.66. MEDEXUS PHARMACEUTIC.’s stock price has changed by +0.00% over the past week, +6.41% over the past month and -19.42% over the last year.
No recent analyst target price found for MEDEXUS PHARMACEUTIC.
No recent average analyst rating found for MEDEXUS PHARMACEUTIC.
Company Overview MEDEXUS PHARMACEUTIC.
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada. Read Less
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intr...Read More
Frequently Asked Questions About MEDEXUS PHARMACEUTIC. (P731:F) Stock
Stock Target Advisor's fundamental analysis for MEDEXUS PHARMACEUTIC.'s stock is Slightly Bearish.
Unfortunately we do not have enough data on P731:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on P731:F's stock to indicate what its average analyst target is.
P731:F stock's Price/Earning ratio is 41.25.
Our analysis grades P731:F stock's Price / Earning ratio at F. This means that P731:F stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this P731:F may be a overvalued for its sector.
The last closing price of P731:F's stock was EUR 1.66.
The most recent market capitalization for P731:F is EUR 0.04B.
Unfortunately we do not have enough analyst data on P731:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MEDEXUS PHARMACEUTIC.'s stock.
As per our most recent records MEDEXUS PHARMACEUTIC. has 82 Employees.
MEDEXUS PHARMACEUTIC.'s registered address is 10 King Street East, Toronto, ON, Canada, M5C 1C3.
You can get more information about it from MEDEXUS PHARMACEUTIC.'s website at https://www.medexus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About MEDEXUS PHARMACEUTIC. (P731:F) Stock
Stock Target Advisor's fundamental analysis for MEDEXUS PHARMACEUTIC.'s stock is Slightly Bearish.
Unfortunately we do not have enough data on P731:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on P731:F's stock to indicate what its average analyst target is.
P731:F stock's Price/Earning ratio is 41.25.
Our analysis grades P731:F stock's Price / Earning ratio at F. This means that P731:F stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this P731:F may be a overvalued for its sector.
The last closing price of P731:F's stock was EUR 1.66.
The most recent market capitalization for P731:F is EUR 0.04B.
Unfortunately we do not have enough analyst data on P731:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MEDEXUS PHARMACEUTIC.'s stock.
As per our most recent records MEDEXUS PHARMACEUTIC. has 82 Employees.
MEDEXUS PHARMACEUTIC.'s registered address is 10 King Street East, Toronto, ON, Canada, M5C 1C3.
You can get more information about it from MEDEXUS PHARMACEUTIC.'s website at https://www.medexus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for P731:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
